These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7226778)

  • 21. Evaluating promising new treatments for life-threatening disease: implications of the HDC/ABMT experience for treating breast cancer.
    Edwards S
    Find Brief; 2005 Jan; 8(1):1-3. PubMed ID: 15672527
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical research. No lifeline for proposed breast cancer prevention trial.
    Kaiser J
    Science; 2007 Jun; 316(5832):1679. PubMed ID: 17588904
    [No Abstract]   [Full Text] [Related]  

  • 23. Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project.
    Newman LA; Mamounas EP
    Surg Clin North Am; 2007 Apr; 87(2):279-305, vii. PubMed ID: 17498527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NIH/NCI Consensus Development Meeting on breast cancer screening. Response of the National Cancer Institute.
    Yale J Biol Med; 1978; 51(1):9-11. PubMed ID: 676352
    [No Abstract]   [Full Text] [Related]  

  • 25. The Breast Cancer Task Force of the National Cancer Institute.
    O'Brien PH
    J S C Med Assoc; 1973 Apr; 69(4):144-5. PubMed ID: 4512224
    [No Abstract]   [Full Text] [Related]  

  • 26. National Cancer Institute breast cancer task force.
    Lipsett MB
    Cancer Res; 1968 Jan; 28(1):155. PubMed ID: 5694116
    [No Abstract]   [Full Text] [Related]  

  • 27. New directions for breast cancer therapeutic research.
    Friedman MA
    Hematol Oncol Clin North Am; 1994 Feb; 8(1):113-9. PubMed ID: 8150774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer institute to tighten control of trials.
    Gavaghan H
    Nature; 1994 Apr; 368(6473):679. PubMed ID: 8152474
    [No Abstract]   [Full Text] [Related]  

  • 29. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
    Buchholz TA; Lehman CD; Harris JR; Pockaj BA; Khouri N; Hylton NF; Miller MJ; Whelan T; Pierce LJ; Esserman LJ; Newman LA; Smith BL; Bear HD; Mamounas EP
    J Clin Oncol; 2008 Feb; 26(5):791-7. PubMed ID: 18258988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Planning combined therapy--the interaction of experimental and clinical studies.
    Carter SK
    Cancer Chemother Rep 2; 1974 Mar; 4(1):3-11. PubMed ID: 4826498
    [No Abstract]   [Full Text] [Related]  

  • 31. Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/ TRICARE; coverage of phase II and phase III clinical trials sponsored by the National Institutes of Health National Cancer Institute. Final rule.
    Office of the Secretary, DoD
    Fed Regist; 2006 Jun; 71(118):35389-91. PubMed ID: 16795948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer research. Budget pressure puts high-profile study in doubt.
    Marshall E
    Science; 2007 Mar; 315(5818):1477. PubMed ID: 17363634
    [No Abstract]   [Full Text] [Related]  

  • 33. National Cancer Institute--supported cancer chemoprevention research: coming of age.
    McCaskill-Stevens W; Hawk ET; Flynn PJ; Lippman SM
    J Clin Oncol; 1999 Nov; 17(11 Suppl):53-62. PubMed ID: 10630263
    [No Abstract]   [Full Text] [Related]  

  • 34. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
    Gralow JR; Burstein HJ; Wood W; Hortobagyi GN; Gianni L; von Minckwitz G; Buzdar AU; Smith IE; Symmans WF; Singh B; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):814-9. PubMed ID: 18258991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the report of the 1966 Cancer Chemotherapy Collaborative Program Review Committee.
    Richardson AP
    Cancer Treat Rep; 1984 Jan; 68(1):340-1. PubMed ID: 6692434
    [No Abstract]   [Full Text] [Related]  

  • 36. NIH and Army meet on breast cancer windfall.
    Watson T
    Nature; 1992 Oct; 359(6398):764. PubMed ID: 1436043
    [No Abstract]   [Full Text] [Related]  

  • 37. Civilian Health and Medical Program of the Uniformed Services (CHAMPUS); methodology for coverage of phase II and phase III clinical trials sponsored by the National Institutes of Health. Office of the Secretary; DoD. Final rule.
    Fed Regist; 2001 Jan; 66(21):8365-6. PubMed ID: 11503809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The "clinical alert" from the National Cancer Institute.
    Lee KC
    N Engl J Med; 1988 Oct; 319(14):948-9. PubMed ID: 3419459
    [No Abstract]   [Full Text] [Related]  

  • 40. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.